ARTICLE
16 September 2026

House Bill Seeks Information On Federal Biotechnology Research And Security

BC
Bergeson & Campbell

Contributor

Bergeson & Campbell, P.C. is a Washington D.C. law firm focusing on chemical product approval and regulation, product defense, and associated business issues. The Acta Group, B&C's scientific and regulatory consulting affiliate provides strategic, comprehensive support for global chemical registration, regulation, and sustained compliance. Together, we help companies that make and use chemicals commercialize their products, maintain compliance, and gain competitive advantage as they market their products globally.
Congressional leaders are pressing federal agencies to demonstrate how they balance advancing U.S. biotechnology research with protecting against emerging biosecurity threats. The inquiry focuses on whether agencies have implemented key recommendations from a national security commission and what additional resources they need to maintain American leadership in this rapidly evolving field.
United States Government, Public Sector
Lynn L. Bergeson Esq.’s articles from Bergeson & Campbell are most popular:
  • within Government and Public Sector topic(s)
Bergeson & Campbell are most popular:
  • within Litigation and Mediation & Arbitration topic(s)

On September 9, 2026, Representatives Brian Babin (R-TX), Chair of the House Science, Space, and Technology Committee, and Rich McCormick (R-GA), Chair of the Investigations and Oversight Subcommittee, sent letters to U.S. Department of Energy (DOE) Secretary Chris Wright, National Institutes of Health (NIH) Director Jay Bhattacharya, and National Science Foundation (NSF) Acting Director Brian Stone requesting information on how those agencies are “advancing U.S. leadership in biotechnology research while protecting against biosecurity and research security risks.” According to the Committee’s September 9, 2026, press release, in the letters, the Chairs highlight the growing importance of biotechnology to U.S. economic competitiveness, scientific leadership, national security, healthcare, agriculture, energy, and manufacturing. The Chairs also emphasize that rapid advances in biotechnology — including synthetic biology, gene editing, deoxyribonucleic acid (DNA) synthesis, automated laboratory technologies, and the convergence of biotechnology and artificial intelligence (AI) — present significant opportunities, as well as emerging security risks. The press release notes that the letters also highlight the National Security Commission on Emerging Biotechnology’s (NSCEB) April 2025 report that identified biotechnology as critical to economic competitiveness, national defense, public health, agriculture, energy, and industrial production. The Chairs ask the agencies to identify any significant gaps, vulnerabilities, or emerging threats related to biotechnology; explain whether they have implemented NSCEB recommendations; and identify any additional authorities, resources, statutory changes, or policy tools needed to strengthen U.S. biotechnology leadership while protecting national security and biosecurity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More